


ONCOLOGY DRUG REPORT

World's Largest Active Resource
for Decision Making

2014

2nd EDITION



- **Largest Coverage with 33 Countries covered Globally**

First of Its Type - Fine Details Oriented Analysis Packed in 1055 Pages Intelligence Report.

- **931 Active Cancer Drug Developers Profiles**

523 Clinical, 360 Preclinical & 48 Discovery Companies Profiles

- **2237 Active Drugs in Development**

Individual Drug Mechanism of Action & Drug Target

- **37 Cancer Indications - Pipeline Analysis**

Market Size and Forecast on 19+ Cancer Indications

- **228 Emerging Cancer Drug Targets Details**

50+ Protein Kinases as Emerging Cancer Drug Targets

OmicsX
Intelligent BioSolutions

report highlights

2237

ACTIVE CANCER DRUGS
IN DEVELOPMENT

931

ACTIVE
COMPANIES

4264

ACTIVE
CANCER DRUG INDICATIONS

Single Report provides **Answers to Many**

COVERAGE

Worldwide **33 Countries Coverage**, with Active 931 Drug Developers Profiles.
Deals, Funding, Technology Partners with Key Decision Makers **e-mail & LinkedIn IDs**.
19 Cancer Indications, with In-depth **Pipeline Analysis & Market Forecast**.
2237 Pipeline Molecules Profiles, **Drug Target & Mechanism of Action**.

FOCUSED DECISION MAKING

Comprehensive Intelligence - Helps to recreate all missing links in **Decision Support**.
Duplication of Information is avoided to generate **Precise & Clear Information**.
Only Oncology treatment focused **Activities and Deals** are included.

SAVE TIME & MONEY

Single Comprehensive Solution greatly reduces time, and keeps **Information at Fingertip's**.
Much **Attractively Priced** in compare to peers.
First Purchase provides an option to upgrade at 50% Discount on next yearly editions.

Active Drug Development Pipeline of 37 Major Cancer Indications



LUNG CANCER (299 Active Molecules)
NSCLC / SCLC Pipeline Analysis & Market Forecast

BREAST CANCER (265 Active Molecules)
 Pipeline Analysis & Market Forecast

PROSTATE CANCER (201 Active Molecules)
 Pipeline Analysis & Market Forecast

OVARIAN CANCER (167 Active Molecules)
 Pipeline Analysis & Market Forecast

COLORECTRAL CANCER (165 Active Molecules)
 Pipeline Analysis & Market Forecast

MELANOMA (166 Active Molecules)
 Pipeline Analysis & Market Forecast

PANCREATIC CANCER (149 Active Molecules)
 Pipeline Analysis & Market Forecast

HEPATOCELLULAR CARCINOMA (107 Active Molecules)
 Pipeline Analysis & Market Forecast

MULTIPLE MYELOMA (80 Active Molecules)
 Pipeline Analysis & Market Forecast

GASTRIC CANCER (58 Active Molecules)
 Pipeline Analysis & Market Forecast

LEUKEMIA / HEMATOLOGICAL MAGLIANCIES
AML / ALL / CML / CLL / Others Pipeline Analysis & Market Forecast

NON-HODGKIN LYMPHOMA (170 Active Molecules)
 Pipeline Analysis & Market Forecast

HODGKIN LYMPHOMA (18 Active Molecules)
 Pipeline Analysis & Market Forecast

BRAIN CANCER INCLUDING GLIOBLASTOMA (149 Molecules)
 Pipeline Analysis & Market Forecast

HEAD & NECK CANCER (67 Active Molecules)
 Pipeline Analysis & Market Forecast

RENAL CELL CARCINOMA (76 Active Molecules)
 Pipeline Analysis & Market Forecast

BLADDER CANCER (49 Active Molecules)
 Pipeline Analysis & Market Forecast


THYROID CANCER (24 Active Molecules)
 Pipeline Analysis & Market Forecast

SARCOMA (62 Active Molecules)
 Pipeline Analysis & Market Forecast

Other Cancer Indications Drug Development Pipeline Includes -

Non-Melanoma Skin Cancer; Cervical Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Endometrial Cancer; Oesophageal Cancer; Biliary Tract Cancer; Gallbladder Cancer; Cholangiocarcinoma; Anal Cancer; Gastrointestinal Stromal Tumor; Waldenstrom's Macroglobulinemia; Anaplastic Astrocytoma; Neuroblastoma; Nasopharynx Cancer; Medulloblastoma; Oral Cancer; Wilm's Tumor & Rare Oncology/Orphan Indications.

DETAILED PIPELINE ANALYSIS
 for **INDIVIDUAL INDICATION COVERING**



COMPLETE INSIGHTS
 on **INDIVIDUAL DISEASE CATEGORY** includes



check **Table of Contents** and **Sample Pages**, for further Idea on Disease Coverage.

CXOs / VPs / Directors

Robust Data at **Fingertips** with validating links
Your Drug's Competitive Position with immense
Partnering Opportunities

Profiles of Emerging Competitors and their
Developmental Strategies



How Report will Help

Business Development Head

Largest **Active & Updated** Companies List
Detailed Profiles to plan **Focused Strategies**
LinkedIn & E-mail IDs of Key Decision Makers
Check current Business **Partners & Investors**



Clinical Directors

Latest Clinical Trial with the
"Last Update Status"

Complete Active
Pipeline Analysis

Identify Clinical Trial
Partners & CRO



ONCOLOGY DRUG REPORT

World's Largest Active Resource
for Decision Making

2014



Investors / Analysts

Bring **More Data under Analysis**
Identify the Net Worth of **Investments**
Forecast the **Real Impact** of assets acquisition
Visualize all possible **Untapped Opportunities**

Drug Developers / Scientists

2200+ Drugs Mechanism of Actions
Identify **first in class & best in class** molecules
Detailed Analysis on **228 Cancer Drug Targets**
Robust Data, helps in Predicting the Future of
Cancer Drug Discovery

Highly Inter-Linked **1055** Pages Intelligence Report divided into **6** Sections

598 pages contains, **523** Active Cancer *Clinical* Companies' Profiles.

Each page profile is written in a mini report format and covers company's complete active clinical, pre-clinical & discovery drug pipeline for various cancer indications, individual drug name(s), targets, mechanism of action, *first in class*, SPA / fast track & orphan drug (FDA/EMA) status; clinical trials latest update status, with links for all active cancer indications to external authentic web source to validate information.

Also contains technological collaborations, drug discovery / development proprietary platform, key investors, oncology focused partnering deals & agreements. Details of key management/ decision makers, their LinkedIn and email IDs; employee numbers; assets valuation, market cap with ticker no. etc.

6 pages
Infographics
Distributes Active 931 cancer drug developing companies among their Geographic Region, year of Incorporation and total employee size.

All together is to identify the complete landscape of current and emerging cancer innovation clusters.

63 pages
Infographics and Tables
are designed to provide the complete insights on 2237 active molecules, present in various developmental stages for cancer treatment.

Descriptive Tables outlines various Monoclonal Antibodies, Antibody Drug Conjugates, Cancer Vaccines, recombinant & synthetic proteins, gene & Virus based therapies, stem cell and other cell based therapies descriptions under clinical & preclinical studies.

Section B also includes 228 Cancer Drug Targets complete coverage along with drugs under development for each target. This helps in clear identification of emerging cancer targets and helps in predicting future of cancer drug development. Special section for Protein Kinases is designed to identify its established and emerging roles. Also Top 10 companies target selection strategies can be easily de-marked.

Tables also includes Top 20 companies details in terms of numbers of molecules in development.

215 pages contains, **360** Active Cancer *Pre-clinical* stage companies' Profiles.

Each company profile contains short description on proprietary drug discovery / development platforms, technological collaborations, partners, key investors and oncology focused major partnering deals & agreements.


Also includes, cancer focused active preclinical and discovery stage pipeline with drug targets and their mechanism of drug action. Key contacts, year of incorporation, assets valuation, employee range, market cap with stock exchange/ticker number, names of key management/decision makers. It provides an immense partnering opportunities in the early drug development stage.

28 pages contains, **48** Active Discovery stage companies profiles. Their proprietary technology platforms, partners, key investors and oncology focused major partnering deals & agreements. Active discovery stage pipeline with drug targets and their mechanism of drug action is also included.

95 Pages
details, Tables and
Featured boxes containing complete updates on clinical developmental profiles of 19 major cancer indications including Lung, Breast, Colorectal, Melanoma, Prostate, Ovarian, Pancreatic, HCC, Gastric, Multiple Myeloma, Leukemia, NHL, Hodgkin Lymphoma, Brain, Head and Neck, RCC, Bladder, Thyroid and Sarcoma.

Each profile contains epidemiology, market forecast, top selling chemotherapies & targeted therapies, PH III pipeline drugs with their clinical trial design & combination drugs, key partners with expected launch. Also contains monoclonal antibodies, vaccine and biologics in development; complete PH II & PH I pipeline with partners.

Top 10 vs. other developer's strategies, total kinases in development for particular indication. Identify 2012 major drug advances, failures and new entrants.



	Oncology Drug Report 2014	Other Reports	Other Databases
Layout	Info graphics/ Tables / Figures / Featured Boxes	Figures & Tables (usually)	Figures & Tables (usually)
Design	Interactive Colourful Design (Easy to read)	Simple Designs	Interactive Complex Design
Updates	Yearly	at release time only	Regularly
Companies Coverage (Clinical)	523 [!]	125-180 Clinical Companies	Large Number with non-active Status
Companies Coverage (Exclusive Preclinical & Discovery)	408 [!]	Usually discovery data is not the part of reports	Updates on Preclinical Companies are missing
Platform Technologies Details	✓	✗	✗
Drugs in Development	2237 Active Cancer Treatment Drugs	300-350 Non Treatment are Included	Large Number with mixed and non-active Info
Individual Drug's Mechanism of Actions	✓	✗	✗
First In Class Details	✓	Limited	Limited
Orphan Drug Indications	Yes (69 active molecules for rare diseases)	Yes (Limited Information)	Yes (Limited with noupdates)
228 Drug Targets Details	✓	May Present	May Present
Total Cancer Indications coverage in single report	37 (Cancer Indications Pipeline Analysis)	Multiple Indications Reports	More Emphasis on Main Indications
DETAILED PIPELINE (Clinical, Pre-Clinical & Discovery)	✓	Usually Ph III and Ph II	✓
Individual Drug's Active Clinical Trials info with update status	✓	✗	✓
Top 10 Companies Drug Development Strategies	✓	✗	✗
Preclinical & Discovery Stage Coverage	1092 (Active Preclinical & Discovery molecules)	100-150 molecules	200-250 molecules
Market Size and Forecast of Individual Indications	✓	✓	✓
Oncology Focused Deals (with size and details)	✓	Depends on Report type	✓
Country Coverage	Worldwide (33 Countries)	US and Europe	US and Europe
LinkedIn & Email Ids	✓	✗	✗
Full References for the validation of Data	✓	✗	✓
Major Emphasis	Bring More Active Data under Analysis	Market Forecast with the help of available data	Bring more disease areas on the same platform
Price in USD	\$ 3490 USD	approx 4500 USD	approx 20000 USD Annual subscription

* Oncology Drug Report's First Edition was published in March 2013, and subsequently new updated editions shall be added every year. The buyers are eligible for 50% discount on Cover price on all upcoming editions (March 2015 onwards) to upgrade intelligence. For any further details kindly mail us at reports@omicsx.com

! Non Active clinical/pre-clinical trials molecules or companies are not considered. Also only Oncology treatment molecules/companies are profiled. No disease care/management, diagnostic molecules are counted/profiled.

your skilled expert in data support

We are a group of highly innovative professionals, working together to provide the real insights on massive growing biological data.

In last few years, we have developed our proprietary pharma intelligence database with over 14,400+ active companies records, and our core focus is to identify & map technology competitiveness of this daily growing list.

Thanks to our 35,000+ Top Management connections on LinkedIn, which helps us with a constant knowledge sharing on their companies, whenever required.

Unique features of **Comprehensive Series**

1 First

Worldwide coverage on active companies to bring more data under analysis and to provide a complete landscape on drug development.

2 Second

All Individual Companies Profiles, covered in single Report, to *cross-check* the intelligence generated in the report, with numerous links to justify all information.

3 Third

LinkedIn & E-mail IDs of all Key Decision Maker(s), to identify and link with focused executives for partnering & business development opportunities.

METHODOLOGY

To present with a comprehensive story we closely monitor all year round activities and follows events, press releases, social media etc., for routine updates.

Also, we subscribes to a large number of extensive & authentic resources to feed our internal Knowledgebase, which together with our primary research & personal interviews enables us to develop a quality and accurate intelligence, in form of *Comprehensive Reports*.

Other Reports in **Comprehensive Series** are:-

Neurology Drug Report 2014 - FIRST EDITION

Infectious Disease Drug Report 2014 - FIRST EDITION

few Report Buyers include

